Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boehringer Ingelheim GmbH

Latest From Boehringer Ingelheim GmbH

Roche’s New Obesity Play Shows Early Promise

CT-388 hits in Phase I, but there is a long way to go before the Carmot acquisition pays off.

Clinical Trials Metabolic Disorders

Alphabet To AI Connect, What Favors Drug Development At Indian Institutes Of Technology

After starring in India’s first CAR-T treatment, the country’s Indian Institutes of Technology, or IITs, are set to expand their drug development footprint. Scrip takes a look at what the Indian equivalents of the Massachusetts Institute of Technology have going for them, including sizeable funding and alumni like Alphabet's CEO.

Research & Development Business Strategies

Boehringer Allies With Quallent For Push On Adalimumab

Boehringer Ingelheim has revealed that it will supply its 50mg/ml adalimumab biosimilar to Quallent Pharmaceuticals in the US, under a recently-announced initiative that also involves Teva and Alvotech’s 100mg/ml Humira rival.

Biosimilars Deals

Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh

Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abexxa Biologics Inc
    • AMAL Therapeutics SA
    • ICD Therapeutics
    • NBE Therapeutics AG
    • SSP Co., Ltd.
    • Vira Therapeutics GmbH (Vira T)